vs
Side-by-side financial comparison of Orion Properties Inc. (ONL) and SCYNEXIS INC (SCYX). Click either name above to swap in a different company.
Orion Properties Inc. is the larger business by last-quarter revenue ($36.3M vs $18.6M, roughly 1.9× SCYNEXIS INC). SCYNEXIS INC runs the higher net margin — 65.7% vs -37.4%, a 103.1% gap on every dollar of revenue. On growth, SCYNEXIS INC posted the faster year-over-year revenue change (1808.5% vs -4.6%). Over the past eight quarters, SCYNEXIS INC's revenue compounded faster (268.5% CAGR vs -4.9%).
SCYNEXIS Inc. is a biotechnology company focused on developing innovative antifungal therapies to address unmet medical needs for difficult-to-treat fungal infections. It targets hospital and specialty care markets, with key product candidates serving immunocompromised patients and other high-risk groups.
ONL vs SCYX — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $36.3M | $18.6M |
| Net Profit | $-13.6M | $12.3M |
| Gross Margin | — | — |
| Operating Margin | -9.3% | 56.3% |
| Net Margin | -37.4% | 65.7% |
| Revenue YoY | -4.6% | 1808.5% |
| Net Profit YoY | -45.0% | 376.5% |
| EPS (diluted) | $-0.24 | $0.25 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $36.3M | — | ||
| Q4 25 | $35.2M | $18.6M | ||
| Q3 25 | $37.1M | $334.0K | ||
| Q2 25 | $37.3M | $1.4M | ||
| Q1 25 | $38.0M | $257.0K | ||
| Q4 24 | $38.4M | $977.0K | ||
| Q3 24 | $39.2M | $660.0K | ||
| Q2 24 | $40.1M | $736.0K |
| Q1 26 | $-13.6M | — | ||
| Q4 25 | $-35.8M | $12.3M | ||
| Q3 25 | $-69.0M | $-8.6M | ||
| Q2 25 | $-25.1M | $-6.9M | ||
| Q1 25 | $-9.4M | $-5.4M | ||
| Q4 24 | $-32.8M | — | ||
| Q3 24 | $-10.2M | $-2.8M | ||
| Q2 24 | $-33.8M | $-14.5M |
| Q1 26 | -9.3% | — | ||
| Q4 25 | -101.5% | 56.3% | ||
| Q3 25 | -185.8% | -2516.5% | ||
| Q2 25 | -67.1% | -701.0% | ||
| Q1 25 | -24.4% | -3350.2% | ||
| Q4 24 | -85.4% | — | ||
| Q3 24 | -25.9% | -1563.6% | ||
| Q2 24 | -84.1% | -1255.0% |
| Q1 26 | -37.4% | — | ||
| Q4 25 | -101.7% | 65.7% | ||
| Q3 25 | -186.0% | -2572.2% | ||
| Q2 25 | -67.3% | -504.8% | ||
| Q1 25 | -24.6% | -2097.7% | ||
| Q4 24 | -85.4% | — | ||
| Q3 24 | -26.1% | -425.5% | ||
| Q2 24 | -84.2% | -1964.4% |
| Q1 26 | $-0.24 | — | ||
| Q4 25 | $-0.63 | $0.25 | ||
| Q3 25 | $-1.23 | $-0.17 | ||
| Q2 25 | $-0.45 | $-0.14 | ||
| Q1 25 | $-0.17 | $-0.11 | ||
| Q4 24 | $-0.59 | — | ||
| Q3 24 | $-0.18 | $-0.06 | ||
| Q2 24 | $-0.60 | $-0.30 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $10.3M | $40.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $608.5M | $49.4M |
| Total Assets | $1.2B | $59.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $10.3M | — | ||
| Q4 25 | $22.4M | $40.0M | ||
| Q3 25 | $32.6M | $37.9M | ||
| Q2 25 | $17.4M | $44.8M | ||
| Q1 25 | $9.4M | $40.6M | ||
| Q4 24 | $15.6M | $59.3M | ||
| Q3 24 | $16.6M | $68.8M | ||
| Q2 24 | $24.2M | $73.0M |
| Q1 26 | — | — | ||
| Q4 25 | $465.0M | — | ||
| Q3 25 | $483.0M | — | ||
| Q2 25 | $483.0M | — | ||
| Q1 25 | $505.0M | — | ||
| Q4 24 | $492.0M | — | ||
| Q3 24 | $485.0M | — | ||
| Q2 24 | $462.0M | — |
| Q1 26 | $608.5M | — | ||
| Q4 25 | $623.2M | $49.4M | ||
| Q3 25 | $658.8M | $36.4M | ||
| Q2 25 | $728.0M | $44.5M | ||
| Q1 25 | $753.5M | $50.5M | ||
| Q4 24 | $763.9M | $55.1M | ||
| Q3 24 | $800.9M | $58.5M | ||
| Q2 24 | $816.1M | $60.4M |
| Q1 26 | $1.2B | — | ||
| Q4 25 | $1.2B | $59.0M | ||
| Q3 25 | $1.2B | $51.1M | ||
| Q2 25 | $1.3B | $60.7M | ||
| Q1 25 | $1.3B | $67.9M | ||
| Q4 24 | $1.3B | $90.6M | ||
| Q3 24 | $1.4B | $99.0M | ||
| Q2 24 | $1.3B | $107.8M |
| Q1 26 | — | — | ||
| Q4 25 | 0.75× | — | ||
| Q3 25 | 0.73× | — | ||
| Q2 25 | 0.66× | — | ||
| Q1 25 | 0.67× | — | ||
| Q4 24 | 0.64× | — | ||
| Q3 24 | 0.61× | — | ||
| Q2 24 | 0.57× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $18.4M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | 51.4% | — |
| Cash ConversionOCF / Net Profit | — | 1.50× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $23.6M | $18.4M | ||
| Q3 25 | $5.7M | $-8.7M | ||
| Q2 25 | $11.6M | $-7.5M | ||
| Q1 25 | $-2.2M | $-7.5M | ||
| Q4 24 | $54.3M | $-24.0M | ||
| Q3 24 | $13.8M | $765.0K | ||
| Q2 24 | $17.0M | $-10.9M |
| Q1 26 | 51.4% | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | — | 1.50× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ONL
| Rental | $36.1M | 100% |
| Fee income from unconsolidated joint venture | $137.0K | 0% |
SCYX
| Glaxosmithkline Intellectual Property | $17.2M | 92% |
| Products | $1.4M | 8% |
